Prescription medication · Selective Norepinephrine Reuptake Inhibitor
atomoxetine
Also sold as Strattera. Atomoxetine is used to treat Attention-Deficit/Hyperactivity Disorder (ADHD).
Data updated 2026-05-15
- 3,228
- FDA reportsLightly reported
- 15
- InteractionsSeveral interactions
- 97% less
- Generic vs brandHuge savings
- 6
- Recall records
What the data shows
atomoxetine (Strattera) is a prescription Selective Norepinephrine Reuptake Inhibitor, among the least-reported drugs the FDA tracks (3,228 FDA reports), whose generic costs a fraction of the brand (about 97% less).
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
atomoxetine (Strattera) is a prescription Selective Norepinephrine Reuptake Inhibitor. Atomoxetine is used to treat Attention-Deficit/Hyperactivity Disorder (ADHD).
Atomoxetine (Strattera) is a medicine that can help people with Attention-Deficit/Hyperactivity Disorder (ADHD). It works by affecting a chemical in the brain called norepinephrine.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$12.67/unit
Generic Price
$0.38/unit
Generic Savings
97%
Generic Available
Yes (8 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
NADAC price trail: ATOMOXETINE HCL 10 MG CAPSULE
Same CMS presentation as the headline generic unit price above (2 effective dates). Adjacent % compares consecutive NADAC releases for this description only, not a patient out-of-pocket quote. Latest step: -7.5% vs prior release.
| Effective | NADAC / unit | vs prior | NDCs |
|---|---|---|---|
| October 23, 2024 | $0.4095/EA | - | 1 |
| December 18, 2024 | $0.3786/EA | -7.5% | 7 |
What it does
Atomoxetine is used to treat Attention-Deficit/Hyperactivity Disorder (ADHD).
Common side effects
Feeling sick to your stomach, Throwing up, Feeling tired
Key warnings
Atomoxetine can increase the risk of suicidal thoughts in children and teenagers.
The sections below are summarized in plain English from atomoxetine's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Atomoxetine works by increasing the amount of norepinephrine in your brain. Norepinephrine is a chemical that helps you pay attention and control your impulses. By increasing norepinephrine, atomoxetine can improve ADHD symptoms.
Side Effects (from patient reports)
Based on 3,228 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for atomoxetine, by number of reports
- Nausea
Nausea
431 reports
- Headache
Headache
407 reports
- Fatigue
Fatigue
401 reports
- Condition Aggravated
Condition Aggravated
395 reports
- Hypertension
Hypertension
388 reports
- Insomnia
Insomnia
381 reports
- Vomiting
Vomiting
381 reports
- Pain
Pain
379 reports
- Arthralgia
Arthralgia
374 reports
- Abdominal Discomfort
Abdominal Discomfort
367 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for atomoxetine each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where atomoxetine sits
atomoxetine has more FDA adverse-event reports than 19% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is atomoxetine; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 3,228 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
3,228
Reports Mentioning Death
879
27.2% of reports — not proof of cause
Hospitalization Reports
1,203
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 3 | NAUSEA | 431 |
| 5 | HEADACHE | 407 |
| 6 | FATIGUE | 401 |
| 7 | CONDITION AGGRAVATED | 395 |
| 8 | HYPERTENSION | 388 |
| 9 | INSOMNIA | 381 |
| 10 | VOMITING | 381 |
| 11 | PAIN | 379 |
| 12 | ARTHRALGIA | 374 |
| 13 | ABDOMINAL DISCOMFORT | 367 |
| 14 | HEPATIC ENZYME INCREASED | 367 |
| 15 | HYPOAESTHESIA | 360 |
| 16 | ABDOMINAL PAIN UPPER | 350 |
| 17 | ALOPECIA | 350 |
| 18 | GENERAL PHYSICAL HEALTH DETERIORATION | 350 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Atomoxetine can increase the risk of suicidal thoughts in children and teenagers. Watch carefully for worsening mood or any unusual changes in behavior. Tell your doctor right away if you have any suicidal thoughts or feelings.
Known Drug Interactions
( 7.3 ) • Albuterol (or other beta 2 agonists) - Action of albuterol on cardiovascular system can be potentiated. 7.4 Albuterol Atomoxetine should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta 2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure. Albuterol (600 mcg iv over 2 hours) induced increases in heart rate and blood pressure.
Mechanism: Atomoxetine can make the effects of albuterol on your heart and blood vessels much stronger. This can cause your heart to beat faster and your blood pressure to rise.
7.9 Drugs that Affect Gastric pH Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) had no effect on atomoxetine bioavailability.
Mechanism: Omeprazole changes the acid levels in the stomach, but this does not change how the body absorbs atomoxetine.
7.2 Effect of CYP2D6 Inhibitors on Atomoxetine In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, fluoxetine, and quinidine) increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in poor metabolizers (PMs). In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and C ss, max is about 3- to 4-fold greater than atomoxetine alone.
Mechanism: Fluoxetine blocks the liver enzyme that breaks down atomoxetine, which causes the levels of atomoxetine in your blood to rise significantly.
7.7 Methylphenidate Coadministration of methylphenidate with atomoxetine did not increase cardiovascular effects beyond those seen with methylphenidate alone.
Mechanism: Taking these two drugs together does not seem to cause extra stress on the heart compared to taking methylphenidate by itself.
Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.
Mechanism: Atomoxetine does not interfere with how warfarin attaches to proteins in the blood, so it should not change how well the blood thinner works.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I open the capsule and sprinkle it on food?
Can I stop taking atomoxetine suddenly?
Will atomoxetine cure my ADHD?
How long does it take for atomoxetine to work?
Can atomoxetine affect my heart?
Can atomoxetine cause liver problems?
Can atomoxetine affect my growth?
Can I drink alcohol while taking atomoxetine?
What should I do if I think I'm having a side effect?
Can I take atomoxetine if I have glaucoma?
What are the common side effects of atomoxetine?
Does atomoxetine interact with other medications?
What drug class is atomoxetine?
Is there a generic version of atomoxetine?
What pregnancy or breastfeeding source fields are listed for atomoxetine?
Has atomoxetine been recalled?
Active Recalls
Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.
Safecor Health, LLC
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Glenmark Pharmaceuticals Inc., USA
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Glenmark Pharmaceuticals Inc., USA
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Glenmark Pharmaceuticals Inc., USA
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Glenmark Pharmaceuticals Inc., USA
CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.
Glenmark Pharmaceuticals Inc., USA
Related Medications in Selective Norepinephrine Reuptake Inhibitor
Other drugs grouped near atomoxetine - same-class peers and common alternatives.
acamprosate
Campral
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking.
Compare with atomoxetine →
alprazolam
Xanax
Alprazolam (Xanax) is a medication that can help you with anxiety and panic disorders.
Compare with atomoxetine →
amitriptyline
Elavil
Amitriptyline is a medicine used to treat depression.
Compare with atomoxetine →
amphetamine/dextroamphetamine
Adderall, Adderall XR
Adderall XR is a stimulant medicine.
Compare with atomoxetine →
aripiprazole
Abilify
Aripiprazole (Abilify) is a medicine used to treat certain mental disorders and mood problems.
Compare with atomoxetine →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for atomoxetine: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 3,228.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 27.23%.
- tigecycline Δ 0.06 pts · 5,878 reports · Glycylcycline Antibiotic 27.17%death share
- morphine Δ 0.25 pts · 72,146 reports · Opioid Analgesic 27.48%death share
- fentanyl Δ 1.23 pts · 95,293 reports · Opioid Analgesic 28.46%death share
- oxycodone Δ 1.31 pts · 180,422 reports · Opioid Analgesic 28.54%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on atomoxetine
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for atomoxetine
The FDA label for atomoxetine (sold under brand names such as Strattera) classifies it as a prescription-only medication in the Selective Norepinephrine Reuptake Inhibitor class. Atomoxetine is used to treat Attention-Deficit/Hyperactivity Disorder (ADHD). Official labeling lists 11 commonly reported side effects, including Feeling sick to your stomach, Throwing up, Feeling tired.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 3,228 voluntary reports. The database also lists 15 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS shows a generic unit cost of $0.38 versus $12.67 for the brand - a 97% generic savings.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history (currently 6 recall records on file), and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: November 1, 2023
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages